Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 6/20 | 0.73 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.70 |
| ▸ | TYMP | P19971 | 9/20 | 0.67 |
| ▸ | PDE2A | O00408 | 1/20 | 0.55 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6271787 | 1.00 | NT5E (0.73) | NT5EADORA1TYMPPDE2AIMPDH2 | |
| SCHEMBL6271785 | 1.00 | NT5E (0.73) | NT5EADORA1TYMPPDE2AIMPDH2 | |
| SCHEMBL29799117 | 0.93 | NT5E (0.65) | NT5EADORA1TYMPIMPDH2 | |
| SCHEMBL8610899 | 0.92 | ADORA1 (0.82) | ADORA1TYMP | |
| SCHEMBL31484253 | 0.92 | ADORA1 (0.82) | ADORA1TYMP | |
| SCHEMBL8610903 | 0.92 | ADORA1 (0.82) | ADORA1TYMP | |
| SCHEMBL10585039 | 0.86 | NT5E (0.74) | NT5EADORA1PDE2A | |
| SCHEMBL10585049 | 0.86 | NT5E (0.74) | NT5EADORA1PDE2A | |
| SCHEMBL30608664 | 0.85 | TYMP (0.58) | NT5EADORA1TYMP | |
| SCHEMBL8359104 | 0.85 | ADORA1 (0.75) | ADORA1TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| WO-2008100447-A2 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | SLC29A1, NUDT1, EIF2AK2 | NT5E 226/4885ADORA1 199/4885TYMP 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.